Medicamen Biotech files ANDA for Bortezomib for injection with USFDA
New Delhi: Medicamen Biotech Limited has announced that the company has successfully filed the first ANDA in eCTD format for BORTEZOMIB for injection 3.5 MG/VIAL with US Food and Drug Administration (USFDA).
"This is major milestone for the Company which will trigger USFDA Audit in due course of time," Medicamen stated in a BSE filing.
The BORTEZOMIB API has been developed in house by its R&D and the API is being manufactured by Shivalik Rasayan Ltd (Holding company of MBL) who has already filed DMF of BORTEZOMIB API with USFDA and have authorised Medicamen Biotech Limited to use the API for manufacture of BORTEZOMIB injection 3.5 MG/VIAL.
Read also: Sanofi-AstraZeneca Beyfortus gets USFDA nod for protection of infants against RSV disease
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.